AASLD Briefs: Merck HCV Combo’s Four- and Six-Week Data Disappoint, Upside Seen For Gilead
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s proprietary two-drug combo, when used with Sovaldi, did not produce strong cure rates in short-term therapy, but an eight-week regimen in treatment-naïve cirrhotic patients may offer an advantage over Harvoni. Also, researchers estimate the total cost to treat HCV and recommend need-based prioritization of therapy.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.